Zai Lab Ltd (ZLAB) saw its stock price plummet 5.3% intraday on Monday, following the company's announcement of a public offering of American Depositary Shares (ADSs). The biopharmaceutical company stated that it expects to close the underwritten public offering of 7,843,137 ADSs at a price of $25.50 per ADS, with underwriters fully exercising their option to purchase an additional 1,176,470 ADSs.

The public offering is expected to result in gross proceeds of approximately $230 million for Zai Lab, before deducting underwriting discounts, commissions, and other expenses. The company plans to use the proceeds for general corporate purposes, including funding research and development activities and working capital needs.

While public offerings often dilute existing shareholders' stakes and put short-term pressure on stock prices, investors may view Zai Lab's move as a strategic decision to raise capital for future growth initiatives and product development. The biopharmaceutical firm, focused on oncology, immunology, neuroscience, and infectious disease treatments, could benefit from the additional funds to advance its pipeline and commercial activities.